What to expect from genomic tumour profiling for lung cancer

The laboratory may examine tissue from a lung biopsy, operation, or another tumour sample. It looks for changes that can influence how cancer cells grow and whether a targeted medicine or immune-based approach should be discussed. The report may also be inconclusive or show a finding without an available treatment.

Your team reads the result alongside the lung cancer type, stage, scan findings, breathing function, previous treatment, and other tumour markers. A molecular report adds detail; it does not replace diagnosis, staging, or a conversation about your priorities.

Ask whether existing tissue is enough and whether a new biopsy could provide better material. Discuss the procedure’s preparation and possible effects if a new sample is proposed. Give the team a complete list of medicines, allergies, and prior cancer treatments.

When the report is ready, ask which findings are actionable, how certain they are, and what treatment options they support. Discuss monitoring, side effects, interactions, and alternatives. Do not alter treatment based on a laboratory phrase without your oncology team’s interpretation.

Get urgent help for severe breathlessness, blue lips, chest pain, coughing blood, new confusion, or sudden weakness. These symptoms require clinical assessment and should not wait for the profiling result or the next routine appointment.

Ask: What molecular question is this test addressing? Is my sample adequate? Which findings could alter treatment? How do the results fit with my tumour type and other markers? What happens if the report is inconclusive? When will we review the options together?